Chronic Kidney Disease

The FDA approved semaglutide to reduce the risk of kidney disease worsening, kidney failure, and death due to CVD in those with T2D and CKD.

Patients who started dialysis as children but were not waitlisted until young adulthood faced worse outcomes than those who were listed before turning 18.

Donor HCV positivity was not associated with acute rejection or recipient mortality 1-year post-renal transplant in HCV-negative recipients.

The new definition uses both age and GFR without body surface area correction to determine the threshold value for hyperfiltration.

Non-Hispanic Black and Hispanic children were less likely to undergo preemptive KT and had longer wait times than non-Hispanic White children.

Findings from the HOPE Consortium Trial suggest PCST can help pain interference and quality of life in patients on hemodialysis experiencing chronic pain.

Patients hospitalized for severe COVID-19 had an accelerated eGFR decline relative to those with pneumonia due to other infections.

Gestational exposure to certain NSAIDs during different trimesters of pregnancy was associated with an increased risk of childhood CKD.

The FDA's decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting for the application.

Matthew Weir, MD discusses how a multidisciplinary approach is reshaping CKD management, with a focus on mitigating cardiovascular events.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.

Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.

The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.

Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.